<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623803</url>
  </required_header>
  <id_info>
    <org_study_id>15-003955</org_study_id>
    <nct_id>NCT02623803</nct_id>
  </id_info>
  <brief_title>Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies</brief_title>
  <official_title>Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if a lidocaine infusion will provide benefit to
      pancreatectomy patients in regards to analgesia and return of bowel function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain reduction</measure>
    <time_frame>During recovery period in the PACU (baseline and 30 minutes)</time_frame>
    <description>Pain will be measured using numerical rating scale (0-10) with rest and coughing. The two time frames will be with the arrival of the patient in the PACU (baseline measurement) and 30 minutes after arrival to PACU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>During recovery period in the PACU up to 4 hours</time_frame>
    <description>Total opioid consumption in recovery room converted to morphine equivalents in mg. The time frame includes the interval of time from patient's arrival to the PACU (baseline) to the time of the patient meeting PACU discharge criteria (up to 4 hours after arrival to PACU).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain reduction</measure>
    <time_frame>Until the end of the first postoperative day (baseline, 8pm on postop day 0, 8am on postop day 1, and 8pm on postop day1).</time_frame>
    <description>Pain will be measured using numerical rating scale (0-10) with rest and coughing. The three time frames include assessment at 8 PM on postop day 0, 8 AM on postop day 1, and 8 PM on postop day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>Until the end of the first postoperative day (up to 24 hours)</time_frame>
    <description>Opioids consumption (converted to equivalence of oral morphine) will be totaled at three separate intervals. The intervals are: intraoperatively (induction to extubation), in the PACU (arrival to PACU to time of meeting PACU discharge criteria), and postoperatively (time of meeting PACU discharge criteria to end of 1st postoperative day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return of bowel function</measure>
    <time_frame>During the hospital stay (up to 48 hours)</time_frame>
    <description>Return of bowel function will be assessed daily starting at the 1st postoperative day. Time of first instance of flatus and/or bowel movement will be as per patient reporting (i.e., morning at 7AM) and recorded in hours since the time of the patient arriving in the recovery room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of recovery assessed via a QoR-15 questionnaire</measure>
    <time_frame>Baseline, at 24 hours and 30 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pancreatectomy</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo D5W</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients undergoing elective open or laparoscopic total pancreatectomies and
             pancreatoduodenectomies (i.e., Whipple procedure), and participating in the Enhanced
             Recovery Protocol (ERP) at Mayo Clinic in Florida.

          -  Age 18 - 80 years old

          -  American Society of Anesthesiologist (ASA) class I - III

          -  BMI &lt; 40

          -  Ability to understand and read English

        Exclusion Criteria:

          -  Not able or willing to sign consent

          -  Intolerance or allergy to opioids, NSAIDS, acetaminophen, or amide-type local
             anesthetics (i.e., lidocaine).

          -  History of epilepsy or currently receiving treatment for seizures

          -  Severe hepatic insufficiency (Child-Pugh Score C)

          -  Renal insufficiency (creatinine clearance less than 30 mL/minute)

          -  Advance heart failure (NY Heart failure stage 3 or greater; Ejection function &lt;30%)

          -  Cardiac arrhythmias: 2nd and 3rd degree heart block, sick sinus syndrome, symptomatic
             bradyarrhythmias, Wolff-Parkinson-White (WPW) syndrome, or Stokes-Adams syndrome; Left
             bundle branch block or bifascicular block; Not to exclude patients the following
             conditions unless clinical circumstance dictate: Atrial fibrillation or atrial
             fluTter; Presence of Implantable Cardioverter Defibrillator (ICD), or pacemakers

          -  Patients on anti-arrhythmic therapy (i.e., digoxin, amiodarone, flecainide, lidocaine,
             sotalol, etc.). Not to exclude patients on beta blockers (i.e., metoprolol, atenolol,
             etc.) unless clinical circumstance dictate

          -  Patients with active psychiatric disorders or cognitive dysfunction

          -  Pregnancy or lactating

          -  Enucleation, central, and distal pancreatectomy

          -  Opioid tolerance (defined as consumption of greater than 30 mg of oxycodone per day)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elird Bojaxhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elird Bojaxhi, MD</last_name>
    <phone>904-953-2000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilana Logvinov, DNP, RN</last_name>
    </contact>
    <investigator>
      <last_name>Elird Bojaxhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DE CLIVE-LOWE SG, DESMOND J, NORTH J. Intravenous lignocaine anaesthesia. Anaesthesia. 1958 Apr;13(2):138-46.</citation>
    <PMID>13521304</PMID>
  </reference>
  <reference>
    <citation>BARTLETT EE, HUTSERANI O. Xylocaine for the relief of postoperative pain. Anesth Analg. 1961 May-Jun;40:296-304.</citation>
    <PMID>14448503</PMID>
  </reference>
  <reference>
    <citation>Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000 Nov;87(11):1480-93. Review.</citation>
    <PMID>11091234</PMID>
  </reference>
  <reference>
    <citation>Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6.</citation>
    <PMID>17197840</PMID>
  </reference>
  <reference>
    <citation>Wallin G, Cassuto J, Högström S, Lindén I, Faxén A, Rimbäck G, Hedner T. Effects of lidocaine infusion on the sympathetic response to abdominal surgery. Anesth Analg. 1987 Oct;66(10):1008-13.</citation>
    <PMID>3631561</PMID>
  </reference>
  <reference>
    <citation>Wheatley RG, Schug SA, Watson D. Safety and efficacy of postoperative epidural analgesia. Br J Anaesth. 2001 Jul;87(1):47-61. Review.</citation>
    <PMID>11460813</PMID>
  </reference>
  <reference>
    <citation>Senagore AJ, Delaney CP, Mekhail N, Dugan A, Fazio VW. Randomized clinical trial comparing epidural anaesthesia and patient-controlled analgesia after laparoscopic segmental colectomy. Br J Surg. 2003 Oct;90(10):1195-9.</citation>
    <PMID>14515286</PMID>
  </reference>
  <reference>
    <citation>Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008 Nov;95(11):1331-8. doi: 10.1002/bjs.6375. Review.</citation>
    <PMID>18844267</PMID>
  </reference>
  <reference>
    <citation>Herroeder S, Pecher S, Schönherr ME, Kaulitz G, Hahnenkamp K, Friess H, Böttiger BW, Bauer H, Dijkgraaf MG, Durieux ME, Hollmann MW. Systemic lidocaine shortens length of hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg. 2007 Aug;246(2):192-200. Erratum in: Ann Surg. 2009 Apr;249(4):701. Dijkgraaf, Omarcel G W [corrected to Dijkgraaf, Marcel G W].</citation>
    <PMID>17667496</PMID>
  </reference>
  <reference>
    <citation>Rimbäck G, Cassuto J, Tollesson PO. Treatment of postoperative paralytic ileus by intravenous lidocaine infusion. Anesth Analg. 1990 Apr;70(4):414-9.</citation>
    <PMID>2316883</PMID>
  </reference>
  <reference>
    <citation>Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, Francis J, Speroff T, Gautam S, Margolin R, Sessler CN, Dittus RS, Bernard GR. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003 Jun 11;289(22):2983-91.</citation>
    <PMID>12799407</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Wengritzky R. Simplified postoperative nausea and vomiting impact scale for audit and post-discharge review. Br J Anaesth. 2012 Mar;108(3):423-9. doi: 10.1093/bja/aer505. Epub 2012 Jan 29.</citation>
    <PMID>22290456</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5.</citation>
    <PMID>10740540</PMID>
  </reference>
  <reference>
    <citation>Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011 Jun;41(6):1073-93. doi: 10.1016/j.jpainsymman.2010.08.016. Review.</citation>
    <PMID>21621130</PMID>
  </reference>
  <reference>
    <citation>Gower ST, Quigg CA, Hunt JO, Wallace SK, Myles PS. A comparison of patient self-administered and investigator-administered measurement of quality of recovery using the QoR-40. Anaesth Intensive Care. 2006 Oct;34(5):634-8.</citation>
    <PMID>17061640</PMID>
  </reference>
  <reference>
    <citation>Hollmann MW, Durieux ME. Local anesthetics and the inflammatory response: a new therapeutic indication? Anesthesiology. 2000 Sep;93(3):858-75. Review.</citation>
    <PMID>10969322</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Elird Bojaxhi, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

